{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T01:35:41Z","timestamp":1789781741860,"version":"4.0.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T00:00:00Z","timestamp":1691712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T00:00:00Z","timestamp":1691712000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychiatr Q"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s11126-023-10045-8","type":"journal-article","created":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T14:02:18Z","timestamp":1691762538000},"page":"541-557","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy and Safety of Aripiprazole in Borderline Personality Disorder: A Systematic Review"],"prefix":"10.1007","volume":"94","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8561-6768","authenticated-orcid":false,"given":"Glauco","family":"Valdivieso-Jim\u00e9nez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1606-3570","authenticated-orcid":false,"given":"Dennis Anthony","family":"Pino-Zavaleta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1201-2984","authenticated-orcid":false,"given":"Susan K.","family":"Campos-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5733-5176","authenticated-orcid":false,"given":"Brando","family":"Ortiz-Saavedra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8932-8437","authenticated-orcid":false,"given":"Mar\u00eda F.","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9158-1108","authenticated-orcid":false,"given":"Vicente Aleixandre","family":"Benites-Zapata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,11]]},"reference":[{"key":"10045_CR1","volume-title":"Fifth Edition, Text Revision (DSM-5-TR)","author":"The Diagnostic and Statistical Manual of Mental Disorders","year":"2022","unstructured":"The Diagnostic and Statistical Manual of Mental Disorders. Fifth Edition, Text Revision (DSM-5-TR). Washington, DC: American Psychiatric Association; 2022."},{"key":"10045_CR2","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.psc.2018.07.008","volume":"41","author":"WD Ellison","year":"2018","unstructured":"Ellison WD, Rosenstein LK, Morgan TA, Zimmerman M. Community and clinical epidemiology of borderline personality disorder. Psychiatr Clin North Am. 2018;41:561\u201373. https:\/\/doi.org\/10.1016\/j.psc.2018.07.008.","journal-title":"Psychiatr Clin North Am"},{"key":"10045_CR3","unstructured":"Instituto Nacional de Salud. Mental \u201cHonorio Delgado \u2013 Hideyo Noguchi\u201d. Nota de Prensa N\u00ba 040 (\u201cHonorio Delgado - Hideyo Noguchi\u201d National Institute of Mental Health. Press Release No. 040). 2015. http:\/\/www.insm.gob.pe\/oficinas\/comunicaciones\/notasdeprensa\/2015\/040.html. Accessed 01 Nov 2022."},{"key":"10045_CR4","unstructured":"National Health and Medical Research Council. Clinical practice guideline for the management of borderline personality disorder. https:\/\/www.nhmrc.gov.au\/file\/4896\/download?token=jyKiMInW. Accessed 01 Nov 2022."},{"key":"10045_CR5","doi-asserted-by":"publisher","first-page":"e521","DOI":"10.4088\/JCP.14com09441","volume":"76","author":"J Paris","year":"2015","unstructured":"Paris J. Why patients with severe personality disorders are overmedicated. J Clin Psychiatry. 2015;76:e521. https:\/\/doi.org\/10.4088\/JCP.14com09441.","journal-title":"J Clin Psychiatry"},{"key":"10045_CR6","doi-asserted-by":"publisher","first-page":"e512","DOI":"10.4088\/JCP.14m09228","volume":"76","author":"C Paton","year":"2015","unstructured":"Paton C, Crawford MJ, Bhatti SF, Patel MX, Barnes TR. The use of psychotropic medication in patients with emotionally unstable personality disorder under the care of UK mental health services. J Clin Psychiatry. 2015;76:e512\u20138. https:\/\/doi.org\/10.4088\/JCP.14m09228.","journal-title":"J Clin Psychiatry"},{"key":"10045_CR7","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.comppsych.2010.11.009","volume":"52","author":"J Barrachina","year":"2011","unstructured":"Barrachina J, Pascual JC, Ferrer M, Soler J, Rufat MJ, Andi\u00f3n O, et al. Axis II comorbidity in borderline personality disorder is influenced by sex, age, and clinical severity. Compr Psychiatry. 2011;52:725\u201330. https:\/\/doi.org\/10.1016\/j.comppsych.2010.11.009.","journal-title":"Compr Psychiatry"},{"key":"10045_CR8","unstructured":"National Collaborating Centre for Mental Health. National Institute for Health and Care Excellence: Guidelines. British psychological society & royal college of psychiatrists. Borderline Personality Disorder: Treatment and Management. Leicester (UK): British Psychological Society (UK). 2009. https:\/\/pubmed.ncbi.nlm.nih.gov\/21796831\/. Accessed 01 Nov 2022."},{"key":"10045_CR9","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/s0149-2918(04)90066-5","volume":"26","author":"A DeLeon","year":"2004","unstructured":"DeLeon A, Patel NC, Crismon ML. Aripiprazole: A comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther. 2004;26:649\u201366. https:\/\/doi.org\/10.1016\/s0149-2918(04)90066-5.","journal-title":"Clin Ther"},{"key":"10045_CR10","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1001\/archpsyc.60.7.681","volume":"60","author":"SG Potkin","year":"2003","unstructured":"Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 2003;60:681\u201390. https:\/\/doi.org\/10.1001\/archpsyc.60.7.681.","journal-title":"Arch Gen Psychiatry"},{"issue":"Supplement 1","key":"10045_CR11","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1097\/01.jcp.0000142282.62336.e9","volume":"24","author":"HA Nasrallah","year":"2004","unstructured":"Nasrallah HA, Newcomer JW. Atypical antipsychotics and metabolic dysregulation: Evaluating the risk\/benefit equation and improving the standard of care. J Clin Psychopharmacol. 2004;24(Supplement 1):S7-14. https:\/\/doi.org\/10.1097\/01.jcp.0000142282.62336.e9.","journal-title":"J Clin Psychopharmacol"},{"key":"10045_CR12","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1089\/cap.2020.0014","volume":"31","author":"N Coustals","year":"2021","unstructured":"Coustals N, M\u00e9nard ML, Cohen D. Aripiprazole in children and adolescents. J Child Adolesc Psychopharmacol. 2021;31:4\u201332. https:\/\/doi.org\/10.1089\/cap.2020.0014.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10045_CR13","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.psiq.2018.11.002","volume":"25","author":"A Benabarre","year":"2018","unstructured":"Benabarre A, Campos JA, Russo F, Cerveri G, Prestia D, Gonz\u00e1lez S, et al. Tratamiento con aripiprazol en la pr\u00e1ctica cl\u00ednica: Consenso de un panel de expertos. Psiquiatr Biol. 2018;25:89\u201395. https:\/\/doi.org\/10.1016\/j.psiq.2018.11.002.","journal-title":"Psiquiatr Biol"},{"key":"10045_CR14","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1521\/pedi_2019_33_445","volume":"35","author":"A Aguglia","year":"2021","unstructured":"Aguglia A, Serafini G, Nebbia J, Salvi V, Martinotti G, Corbo M, et al. Off-label use of second-generation antipsychotics in borderline personality disorder: A survey of Italian psychiatrists. J Pers Disord. 2021;35:321\u201335. https:\/\/doi.org\/10.1521\/pedi_2019_33_445.","journal-title":"J Pers Disord"},{"key":"10045_CR15","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.euroneuro.2015.03.017","volume":"25","author":"R Bridler","year":"2015","unstructured":"Bridler R, H\u00e4berle A, M\u00fcller ST, Cattapan K, Grohmann R, Toto S, et al. Psychopharmacological treatment of 2195 in-patients with borderline personality disorder: A comparison with other psychiatric disorders. Eur Neuropsychopharmacol. 2015;25:763\u201372. https:\/\/doi.org\/10.1016\/j.euroneuro.2015.03.017.","journal-title":"Eur Neuropsychopharmacol"},{"key":"10045_CR16","unstructured":"The Cochrane Collaboration Cochrane Handbook for Systematic Reviews of Interventions, version 5.1.0, updated Mar 2011. http:\/\/www.cochrane-handbook.org. Accessed 01 Nov 2022."},{"key":"10045_CR17","unstructured":"Cochrane methods bias. RoB 2: A revised Cochrane risk-of-bias tool for randomized trials. https:\/\/methods.cochrane.org\/bias\/resources\/rob-2-revised-cochrane-risk-bias-tool-randomized-trials. Accessed 01 Nov 2022."},{"key":"10045_CR18","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/s12888-016-1014-3","volume":"16","author":"Y Sereda","year":"2016","unstructured":"Sereda Y, Dembitskyi S. Validity assessment of the symptom checklist SCL-90-R and shortened versions for the general population in Ukraine. BMC Psychiatry. 2016;16:300. https:\/\/doi.org\/10.1186\/s12888-016-1014-3.","journal-title":"BMC Psychiatry"},{"key":"10045_CR19","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/j.2044-8260.1967.tb00530.x","volume":"6","author":"M Hamilton","year":"1967","unstructured":"Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967;6:278\u201396. https:\/\/doi.org\/10.1111\/j.2044-8260.1967.tb00530.x.","journal-title":"Br J Soc Clin Psychol"},{"key":"10045_CR20","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","volume":"32","author":"M Hamilton","year":"1959","unstructured":"Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32:50\u20135. https:\/\/doi.org\/10.1111\/j.2044-8341.1959.tb00467.x.","journal-title":"Br J Med Psychol"},{"key":"10045_CR21","doi-asserted-by":"publisher","first-page":"21","DOI":"10.14349\/sumapsi.2018.v25.n1.3","volume":"25","author":"ZE Garc\u00eda-Batista","year":"2018","unstructured":"Garc\u00eda-Batista ZE, Guerra-Pe\u00f1a K, Cano-Vindel A, Herrera-Mart\u00ednez SX, Flores-Kanter PE, Medrano LA. Evidencias de validez y fiabilidad de las Puntuaciones del STAXI-2 para poblaci\u00f3n general y hospitalaria: Estudio con una muestra de adultos de Rep\u00fablica Dominicana. Suma Psicol. 2018;25:21\u20139. https:\/\/doi.org\/10.14349\/sumapsi.2018.v25.n1.3.","journal-title":"Suma Psicol"},{"key":"10045_CR22","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/0005-7967(94)00043-J","volume":"33","author":"A Lange","year":"1995","unstructured":"Lange A, Pahlich A, Sarucco M, Smits G, Dehghani B, Hanewald G. Psychometric characteristics and validity of the Dutch adaptation of the Buss-Durkee Hostility Inventory (the BDHI-D). Behav Res Ther. 1995;33:223\u20137. https:\/\/doi.org\/10.1016\/0005-7967(94)00043-J.","journal-title":"Behav Res Ther"},{"key":"10045_CR23","first-page":"1081","volume":"89","author":"MB Lee","year":"1990","unstructured":"Lee MB, Lee YJ, Yen LL, Lin MH, Lue BH. Reliability and validity of using a Brief Psychiatric Symptom Rating Scale in clinical practice. J Formos Med Assoc. 1990;89:1081\u20137.","journal-title":"J Formos Med Assoc"},{"key":"10045_CR24","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1111\/j.1365-2753.2007.00921.x","volume":"14","author":"M Berk","year":"2008","unstructured":"Berk M, Ng F, Dodd S, Callaly T, Campbell S, Bernardo M, Trauer T. The validity of the CGI severity and improvement scales as measures of clinical effectiveness suitable for routine clinical use. J Eval Clin Pract. 2008;14:979\u201383. https:\/\/doi.org\/10.1111\/j.1365-2753.2007.00921.x.","journal-title":"J Eval Clin Pract"},{"key":"10045_CR25","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1176\/ajp.2006.163.5.833","volume":"163","author":"MK Nickel","year":"2006","unstructured":"Nickel MK, Muehlbacher M, Nickel C, Kettler C, Pedrosa Gil FP, Bachler E, et al. Aripiprazole in the treatment of patients with borderline placebo-controlled study. Am J Psychiatry. 2006;163:833\u20138. https:\/\/doi.org\/10.1176\/ajp.2006.163.5.833.","journal-title":"Am J Psychiatry"},{"key":"10045_CR26","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s00213-007-0740-0","volume":"191","author":"MK Nickel","year":"2007","unstructured":"Nickel MK, Loew TH, Pedrosa Gil FP. Aripiprazole in treatment of borderline patients, part II: An 18-month follow-up. Psychopharmacol (Berl). 2007;191:1023\u20136. https:\/\/doi.org\/10.1007\/s00213-007-0740-0.","journal-title":"Psychopharmacol (Berl)"},{"key":"10045_CR27","doi-asserted-by":"publisher","DOI":"10.2174\/2211556003666140912223626","author":"SS Shafti","year":"2014","unstructured":"Shafti SS, Kaviani H. Olanzapine vs aripiprazole in the management of borderline personality disorder. Curr Psychopharmacol. 2014. https:\/\/doi.org\/10.2174\/2211556003666140912223626.","journal-title":"Curr Psychopharmacol"},{"key":"10045_CR28","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1521\/pedi.2009.23.2.156","volume":"23","author":"D Mercer","year":"2009","unstructured":"Mercer D, Douglass AB, Links PS. Meta-analyses of mood stabilizers, antidepressants and antipsychotics in the treatment of borderline personality disorder: Effectiveness for depression and anger symptoms. J Pers Disord. 2009;23:156\u201374. https:\/\/doi.org\/10.1521\/pedi.2009.23.2.156.","journal-title":"J Pers Disord"},{"key":"10045_CR29","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1192\/bjp.bp.108.062984","volume":"196","author":"K Lieb","year":"2010","unstructured":"Lieb K, V\u00f6llm B, R\u00fccker G, Timmer A, Stoffers JM. Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials. Br J Psychiatry. 2010;196:4\u201312. https:\/\/doi.org\/10.1192\/bjp.bp.108.062984.","journal-title":"Br J Psychiatry"},{"key":"10045_CR30","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.2174\/092986711796504682","volume":"18","author":"S Bellino","year":"2011","unstructured":"Bellino S, Rinaldi C, Bozzatello P, Bogetto F. Pharmacotherapy of borderline personality disorder: A systematic review for publication purpose. Curr Med Chem. 2011;18:3322\u20139. https:\/\/doi.org\/10.2174\/092986711796504682.","journal-title":"Curr Med Chem"},{"key":"10045_CR31","doi-asserted-by":"publisher","first-page":"CD005653","DOI":"10.1002\/14651858.CD005653.pub2","volume":"6","author":"J Stoffers","year":"2010","unstructured":"Stoffers J, V\u00f6llm BA, R\u00fccker G, Timmer A, Huband N, Lieb K. Pharmacological interventions for borderline personality disorder. Cochrane Database Syst Rev. 2010;6:CD005653. https:\/\/doi.org\/10.1002\/14651858.CD005653.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"10045_CR32","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1177\/070674371405901103","volume":"59","author":"BJ Turner","year":"2014","unstructured":"Turner BJ, Austin SB, Chapman AL. Treating nonsuicidal self-injury: A systematic review of psychological and pharmacological interventions. Can J Psychiatry. 2014;59:576\u201385. https:\/\/doi.org\/10.1177\/070674371405901103.","journal-title":"Can J Psychiatry"},{"key":"10045_CR33","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.psc.2018.07.012","volume":"41","author":"MM Perez-Rodriguez","year":"2018","unstructured":"Perez-Rodriguez MM, Bulbena-Cabr\u00e9 A, Bassir Nia A, Zipursky G, Goodman M, New AS. The neurobiology of borderline personality disorder. Psychiatr Clin North Am. 2018;41:633\u201350. https:\/\/doi.org\/10.1016\/j.psc.2018.07.012.","journal-title":"Psychiatr Clin North Am"},{"key":"10045_CR34","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1159\/000297734","volume":"61","author":"B Dell\u2019Osso","year":"2010","unstructured":"Dell\u2019Osso B, Berlin HA, Serati M, Altamura AC. Neuropsychobiological aspects, comorbidity patterns and dimensional models in borderline personality disorder. Neuropsychobiology. 2010;61:169\u201379. https:\/\/doi.org\/10.1159\/000297734.","journal-title":"Neuropsychobiology"},{"key":"10045_CR35","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/HRP.0000000000000123","volume":"24","author":"AC Ruocco","year":"2016","unstructured":"Ruocco AC, Carcone D. A neurobiological model of borderline personality disorder: Systematic and integrative review. Harv Rev Psychiatry. 2016;24:311\u201329. https:\/\/doi.org\/10.1097\/HRP.0000000000000123.","journal-title":"Harv Rev Psychiatry"},{"key":"10045_CR36","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3389\/fgene.2013.00313","volume":"4","author":"PR Joyce","year":"2014","unstructured":"Joyce PR, Stephenson J, Kennedy M, Mulder RT, McHugh PC. The presence of both serotonin 1A receptor (HTR1A) and dopamine transporter (DAT1) gene variants increase the risk of borderline personality disorder. Front Genet. 2014;4:313. https:\/\/doi.org\/10.3389\/fgene.2013.00313.","journal-title":"Front Genet"},{"key":"10045_CR37","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1744-9081-6-4","volume":"6","author":"Z Nemoda","year":"2010","unstructured":"Nemoda Z, Lyons-Ruth K, Szekely A, Bertha E, Faludi G, Sasvari-Szekely M. Association between dopaminergic polymorphisms and borderline personality traits among at-risk young adults and psychiatric inpatients. Behav Brain Funct. 2010;6:4. https:\/\/doi.org\/10.1186\/1744-9081-6-4.","journal-title":"Behav Brain Funct"},{"key":"10045_CR38","doi-asserted-by":"publisher","first-page":"711940","DOI":"10.3389\/fphar.2021.711940","volume":"12","author":"P Soria-Chacartegui","year":"2021","unstructured":"Soria-Chacartegui P, Villapalos-Garc\u00eda G, Zubiaur P, Abad-Santos F, Koller D. Genetic polymorphisms associated with the pharmacokinetics, pharmacodynamics and adverse effects of olanzapine, aripiprazole and risperidone. Front Pharmacol. 2021;12:711940. https:\/\/doi.org\/10.3389\/fphar.2021.711940.","journal-title":"Front Pharmacol"}],"container-title":["Psychiatric Quarterly"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11126-023-10045-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11126-023-10045-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11126-023-10045-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T08:01:43Z","timestamp":1699603303000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11126-023-10045-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,11]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10045"],"URL":"https:\/\/doi.org\/10.1007\/s11126-023-10045-8","relation":{},"ISSN":["0033-2720","1573-6709"],"issn-type":[{"value":"0033-2720","type":"print"},{"value":"1573-6709","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,11]]},"assertion":[{"value":"27 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}